2015年3月12日 讯/生物谷BIOON/ --安捷伦旗下公司丹麦丹科与日本小野药品株式会社合作共同开发一项配套用于小野药品株式会社和美国Bristol-Myers Squibb's公司的治疗非小细胞肺癌的药物Opdivo，以此来增强他们在诊断方面的合作伙伴关系并期望在这个领域得到更多的收益。
双方对财务细节都保持沉默，但丹科将帮助研发一种诊断测试，用于判断哪些患者适合使用小野和BMS's的癌症治疗。肺癌是全球最常见的死亡原因，而Opdivo是一种PD-1的抑制剂，用于治疗非小细胞肺癌，能够阻断癌症细胞常用的免疫逃逸机制，从而使肿瘤细胞被杀伤。非小细胞型肺癌包括鳞状细胞癌（鳞癌）、腺癌、大细胞癌，与小细胞癌相比其癌细胞生长分裂较慢,扩散转移相对较晚。非小细胞肺癌约占所有肺癌的80%，约75%的患者发现时已处于中晚期，5年生存率很低。
安捷伦主席Jacob Thaysen在一份声明中说："能被小野药品选为合作伙伴开发配套使用的诊断技术我们非常高兴。今日的声明之前安捷伦-丹科的业务中已有急性其它的关于诊断方面的合作协议。"
安捷伦在2012年斥资22亿美元收购丹科进军诊断市场。2013年1月，安捷伦表示将于礼来合作为药商开发测试癌症管道介入治疗的检测技术。去年，丹科与默克合作开发了该公司肿瘤管道治疗的配套检测技术。丹科还与制药巨头安进、辉瑞和罗氏达成协议开发新的检测。
Dako joins up with Ono to develop cancer companion Dx
Denmark's Dako is teaming up with Ono Pharmaceutical to develop a test for Ono and Bristol-Myers Squibb's ($BMY) drug for non-small cell lung cancer (NSCLC), Opdivo, adding to its tally of companion diagnostics partnerships and gaining more ground in the field.
Both sides are staying mum on financial details, but Dako, now owned by Agilent Technologies ($A), will help create a companion diagnostic test to identify which patients are a good fit for Ono and BMS' investigational cancer treatment. Lung cancer is the most common cause of cancer-related death worldwide, and Opdivo, a PD-1 inhibitor, blocks a mechanism cancer cells use to escape detection by the body's immune system.
"We are pleased to be chosen as Ono's partner for the development of a companion diagnostic test for this promising drug. Today's announcement follows several other collaborative agreements in the companion diagnostics area by Agilent's Dako business," Jacob Thaysen, president of Agilent's Diagnostics and Genomics group, said in a statement. Dako has been on a companion diagnostics roll since Agilent scooped up the company in 2012 for $2.2 billion, inking deals to expand its market footprint. In January 2013, the company said it would join forces with Eli Lilly ($LLY) to develop tests for the drugmaker's pipeline cancer treatments.
Last year, Dako teamed up with Merck ($MRK) to create companion diagnostics for the company's oncology pipeline. Dako has also forged deals with pharma heavyweights Amgen ($AMGN), Pfizer ($PFE) and Roche ($RHHBY) to develop tests for new treatments.